Literature DB >> 16222669

Frontal lobe epilepsy and mutations of the corticotropin-releasing hormone gene.

Romina Combi1, Leda Dalprà, Luigi Ferini-Strambi, Maria L Tenchini.   

Abstract

Nocturnal frontal lobe epilepsy up to now has been considered a channelopathy caused by mutations in the alpha(4) and beta(2) subunits of the neuronal nicotinic acetylcholine receptor. However, these mutations account for only a minority of patients, and the existence of at least a new locus for the disease has been demonstrated. In one Italian nocturnal frontal lobe epilepsy family, we identified two new putative loci on chromosomes 3 and 8, where several candidate genes are mapped. In particular, on chromosome 8, corticotropin-releasing hormone gene (CRH) appears to be a good candidate. We therefore searched for CRH mutations in the proband. The study allowed the identification of a nucleotide variation in the promoter that was subsequently detected in all affected and obligate carrier members of the same family, in two sporadic cases, in all affected members of an additional compliant family, and in the proband of a noncompliant family. Moreover, a different mutation in the promoter was detected in a familial case. In vitro experiments showed altered levels of gene expression. CRH alterations could explain several autosomal dominant nocturnal frontal lobe epilepsy clinical features.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16222669     DOI: 10.1002/ana.20660

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

Review 1.  Nocturnal frontal lobe epilepsy.

Authors:  Lino Nobili; Paola Proserpio; Romina Combi; Federica Provini; Giuseppe Plazzi; Francesca Bisulli; Laura Tassi; Paolo Tinuper
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

Review 2.  Genetic basis in epilepsies caused by malformations of cortical development and in those with structurally normal brain.

Authors:  Danielle M Andrade
Journal:  Hum Genet       Date:  2009-06-18       Impact factor: 4.132

Review 3.  Neuronal nicotinic receptors in sleep-related epilepsy: studies in integrative biology.

Authors:  Andrea Becchetti
Journal:  ISRN Biochem       Date:  2012-12-09

Review 4.  The role of nicotinic acetylcholine receptors in autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Andrea Becchetti; Patrizia Aracri; Simone Meneghini; Simone Brusco; Alida Amadeo
Journal:  Front Physiol       Date:  2015-02-11       Impact factor: 4.566

Review 5.  Genome annotation for clinical genomic diagnostics: strengths and weaknesses.

Authors:  Charles A Steward; Alasdair P J Parker; Berge A Minassian; Sanjay M Sisodiya; Adam Frankish; Jennifer Harrow
Journal:  Genome Med       Date:  2017-05-30       Impact factor: 11.117

Review 6.  Nicotinic Receptors in Sleep-Related Hypermotor Epilepsy: Pathophysiology and Pharmacology.

Authors:  Andrea Becchetti; Laura Clara Grandi; Giulia Colombo; Simone Meneghini; Alida Amadeo
Journal:  Brain Sci       Date:  2020-11-25

Review 7.  Pharmacogenetics of Drug-Resistant Epilepsy (Review of Literature).

Authors:  Beata Smolarz; Marianna Makowska; Hanna Romanowicz
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

8.  A novel missense creatine mutant of CaBP4, c.464G>A (p.G155D), associated with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), reduces the expression of CaBP4.

Authors:  Yuxiong Guo; Qinfei Miao; Yuxin Zhang; Chun Wang; Mingjuan Liang; Xueping Li; Weifeng Qiu; Gangan Shi; Qiongxiang Zhai; Zhihong Chen
Journal:  Transl Pediatr       Date:  2022-03

9.  Functional characterization of a CRH missense mutation identified in an ADNFLE family.

Authors:  Veronica Sansoni; Matilde Forcella; Alessandra Mozzi; Paola Fusi; Roberto Ambrosini; Luigi Ferini-Strambi; Romina Combi
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

Review 10.  Can rodent models elucidate the pathomechanisms of genetic epilepsy?

Authors:  Motohiro Okada
Journal:  Br J Pharmacol       Date:  2021-05-12       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.